Darcy Lewis | Authors

Articles

RET, MET Inhibitors Advance Targeted Therapies in NSCLC

December 28, 2020

FDA approvals of novel agents for molecularly defined subtypes of non–small cell lung cancer are poised to change both patient outcomes as well as pretreatment testing requirements for those harboring these tumors.